Calendario de promoción Mereo BioPharma Group plc
Horario avanzado
gráfico sencillo
Acerca de la empresa
Mereo BioPharma Group plc, биофармацевтическая компания, разрабатывает и продает терапевтические средства для лечения онкологии и редких заболеваний в Великобритании и за рубежом. Ведущий продукт-кандидат, этигилимаб (OMP-313M32), антитело Т-клеточного иммунорецептора с доменами Ig и ITIM, которое проходит фазу 1b клинических испытаний для лечения опухолей.
Más detalles| Выручка | -0.000162 |
|---|---|
| EBITDA | -0.0498 |
| P/E | 48.69 |
| P/S | -1554.04 |
| EV/EBITDA | -5.48 |
| Цена ао | 2.97 |
| P/BV | 4.71 |
| Сайт | https://www.mereobiopharma.com |
| ISIN | US5894921072 |
| Число акций ао | 0.65945 млрд |
| Валюта | usd |
| IPO date | 2019-04-24 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Cambio de precio por día: | 0% (4.34) |
|---|---|
| Cambio de precio por semana.: | +2.12% (4.25) |
| Cambio de precio por mes: | +1.4% (4.28) |
| Cambio de precio en 3 meses.: | +6.11% (4.09) |
| Cambio de precio en seis meses: | +68.22% (2.58) |
| Cambio de precio por año: | +171.25% (1.6) |
| Cambio de precio en 3 años.: | +92.89% (2.25) |
| Cambio de precio en 5 años.: | +29.94% (3.34) |
| Cambio de precio desde principios de año.: | +108.15% (2.085) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Fecha de transacción | fecha de divulgación | Persona enterada | Tipo | Precio | Volumen | Cantidad | Comparte hasta, % | compartir después, % | Documento |
|---|---|---|---|---|---|---|---|---|---|
| 12.09.2024 | 12.09.2024 | Fox Christine Ann Officer |
Compra | 4.66 | 131 813 | 28286 | 0 | 0.03 | enlace |
| 12.09.2024 | 12.09.2024 | Sermon Charles Officer |
Compra | 4.66 | 144 115 | 30926 | 0 | 0.03 | enlace |
| 12.09.2024 | 12.09.2024 | Alexandra Hughes-Wilson Officer |
Compra | 4.66 | 690 193 | 148110 | 0 | 0.14 | enlace |
| 12.09.2024 | 12.09.2024 | Lewicki John A. Officer |
Compra | 4.66 | 75 254 | 16149 | 0 | 0.01 | enlace |
| 12.09.2024 | 12.09.2024 | Scots-Knight Denise Officer |
Compra | 4.66 | 413 142 | 88657 | 0 | 0.08 | enlace |
| 26.06.2024 | 27.06.2024 | Hughes-Wilson Alexandra See Remarks |
Venta | 3.39 | 77 862 | 22968 | 0 | -0.02 | enlace |
| 26.06.2024 | 27.06.2024 | Scots-Knight Denise Chief Executive Officer |
Venta | 3.39 | 312 805 | 92273 | 0 | -0.08 | enlace |
| 26.06.2024 | 27.06.2024 | Fox Christine Ann Chief Financial Officer |
Venta | 3.39 | 99 798 | 29439 | 0 | -0.03 | enlace |
| 26.06.2024 | 27.06.2024 | Lewicki John A. Chief Scientific Officer |
Venta | 3.39 | 56 979 | 16808 | 0 | -0.02 | enlace |
| 26.06.2024 | 27.06.2024 | Sermon Charles General Counsel |
Venta | 3.39 | 109 114 | 32187 | 0 | -0.03 | enlace |
| 25.06.2024 | 27.06.2024 | Hughes-Wilson Alexandra See Remarks |
Venta | 3.69 | 37 394 | 10134 | 0 | -0.01 | enlace |
| 25.06.2024 | 27.06.2024 | Scots-Knight Denise Chief Executive Officer |
Venta | 3.69 | 150 227 | 40712 | 0 | -0.04 | enlace |
| 25.06.2024 | 27.06.2024 | Fox Christine Ann Chief Financial Officer |
Venta | 3.69 | 47 933 | 12990 | 0 | -0.01 | enlace |
| 25.06.2024 | 27.06.2024 | Lewicki John A. Chief Scientific Officer |
Venta | 3.69 | 27 365 | 7416 | 0 | -0.01 | enlace |
| 25.06.2024 | 27.06.2024 | Sermon Charles General Counsel |
Venta | 3.69 | 52 405 | 14202 | 0 | -0.01 | enlace |
| 21.06.2024 | 25.06.2024 | Hughes-Wilson Alexandra See Remarks |
Compra | 4.25 | 255 000 | 60000 | 0 | 0.06 | enlace |
| 22.05.2024 | 23.05.2024 | Hughes-Wilson Alexandra See Remarks |
Venta | 2.97 | 298 283 | 100432 | 0 | -0.09 | enlace |
| 22.05.2024 | 23.05.2024 | Hughes-Wilson Alexandra See Remarks |
Compra | 1.23 | 207 050 | 168333 | 0 | 0.15 | enlace |
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Rubric Capital Management LP | 10366120 | 15.3 |
| Orbimed Advisors LLC. | 7747891 | 11.44 |
| Suvretta Capital Management, LLC | 7364438 | 10.87 |
| Rock Springs Capital Management, LP | 6244897 | 9.22 |
| Citadel Advisors Llc | 3047960 | 4.5 |
| Millennium Management LLC | 2505630 | 3.7 |
| Tejara Capital Ltd | 2435806 | 3.6 |
| Alkeon Capital Management LLC | 2385600 | 3.52 |
| Goldman Sachs Group Inc | 2262785 | 3.34 |
| Boxer Capital, LLC | 2250000 | 3.32 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Ms. Christine Fox CPA | Chief Financial Officer | N/A | 1981 (43 año) |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer | N/A | 1952 (72 año) |
| Dr. Jackie Parkin | Senior VP & Therapeutic Head | N/A | 1958 (66 años) |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | N/A | 1971 (53 año) |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development | N/A | 1965 (59 años) |
| Dr. John P. Richard M.B.A. | Co-Founder & Chief Business Officer | N/A | 1957 (67 años) |
| Mr. Bo Kara | Senior VP and Head of Pharmaceutical Development & CMC | N/A | |
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, CEO & Executive Director | 1959 (65 años) | |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | 1969 (55 años) |
DIRECCIÓN: United Kingdom, London WG QF, One Cavendish Place - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.mereobiopharma.com
Sitio web: https://www.mereobiopharma.com
